Bendamustine
(Redirected from Vivimusta)
.png)
Bendamustine is a chemotherapy medication used in the treatment of certain types of cancer. It is classified as an alkylating agent and is primarily used to treat chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Bendamustine is known for its unique mechanism of action, which combines properties of both alkylating agents and antimetabolites.
Medical Uses[edit | edit source]
Bendamustine is indicated for the treatment of:
- Chronic lymphocytic leukemia (CLL)
- Non-Hodgkin lymphoma (NHL), particularly in patients who have not responded to other treatments
Mechanism of Action[edit | edit source]
Bendamustine works by causing DNA damage in cancer cells, which leads to cell death. It forms cross-links between DNA strands, preventing the cancer cells from dividing and growing. This dual mechanism of action, involving both alkylation and antimetabolite activity, makes bendamustine effective against cancer cells that may be resistant to other treatments.
Administration[edit | edit source]
Bendamustine is administered intravenously. The dosage and treatment schedule depend on the type of cancer being treated, the patient's overall health, and other factors. It is typically given in cycles, with periods of treatment followed by periods of rest.
Side Effects[edit | edit source]
Common side effects of bendamustine include:
- Nausea
- Vomiting
- Fatigue
- Fever
- Infections due to lowered white blood cell counts
- Anemia
- Thrombocytopenia
Serious side effects can include severe infections, allergic reactions, and secondary cancers.
History[edit | edit source]
Bendamustine was first synthesized in the 1960s in the former East Germany. It was approved for medical use in the United States by the Food and Drug Administration (FDA) in 2008.
Research[edit | edit source]
Ongoing research is exploring the use of bendamustine in combination with other chemotherapy agents and targeted therapies to improve outcomes for patients with various types of cancer.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
